The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease
Abstract
BACKGROUND: Cystatin C is an alternative measure of kidney function that may have prognostic importance among elderly persons who do not meet standard criteria for chronic kidney disease (estimated glomerular filtration rate [GFR] > or =60 mL/min per 1.73 m2). OBJECTIVE: To evaluate cystatin C as a prognostic biomarker for death, cardiovascular disease, and incident chronic kidney disease among elderly persons without chronic kidney disease. DESIGN: Cohort study. SETTING: The Cardiovascular Health Study, a population-based cohort recruited from 4 communities in the United States. PARTICIPANTS: 4663 elderly persons. MEASUREMENTS: Measures of kidney function were creatinine-based estimated GFR by using the Modification of Diet in Renal Disease equation and cystatin C concentration. Outcomes were death, cardiovascular death, noncardiovascular death, heart failure, stroke, myocardial infarction, and incident chronic kidney disease during follow-up (median, 9.3 years). RESULTS: At baseline, 78% of participants did not have chronic kidney disease (estimated GFR > or =60 mL/min per 1.73 m2) and mean cystatin C concentration, creatinine concentration, and estimated GFR were 1.0 mg/L, 79.6 micromol/L (0.9 mg/dL), and 83 mL/min per 1.73 m2, respectively. Cystatin C concentrations (per SD, 0.18 mg/L) had strong associations with death (hazard ratio, 1.33 [95% CI, 1.25 to 1.40]), cardiovascular death (hazard ratio, 1.42 [CI, 1.30 to 1.54]), noncardiovascular death (hazard ratio, 1.26 [CI, 1.17 to 1.36]), incident heart failure (hazard ratio, 1.28 [CI, 1.17 to 1.40]), stroke (hazard ratio, 1.22 [CI, 1.08 to 1.38]), and myocardial infarction (hazard ratio, 1.20 [CI, 1.06 to 1.36]) among these participants. Serum creatinine concentrations had much weaker associations with each outcome and only predicted cardiovascular death. Participants without chronic kidney disease who had elevated cystatin C concentrations (> or =1.0 mg/L) had a 4-fold risk for progressing to chronic kidney disease after 4 years of follow-up compared with those with cystatin C concentrations less than 1.0 mg/L. LIMITATIONS: Because this study did not directly measure GFR or albuminuria, the extent to which cystatin C may be influenced by nonrenal factors was not determined and participants with albuminuria might have been misclassified as having no kidney disease. CONCLUSIONS: Among elderly persons without chronic kidney disease, cystatin C is a prognostic biomarker of risk for death, cardiovascular disease, and chronic kidney disease. In this setting, cystatin C seems to identify a "preclinical" state of kidney dysfunction that is not detected with serum creatinine or estimated GFR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Levey, A. S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D. D. E., Hostetter, T. H., Lameire, N., & Eknoyan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00365.x · Cited by 3,946
Flexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652 · cited 2×
“The study design, quality control procedures, laboratory methods, and blood pressure measurement procedures have been published previously (9, 10).”
BackgroundMethodSelf-citationSerum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis
Dharnidharka, V. R., Kwon, C., & Stevens, G. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.34487 · Cited by 1,663
Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons
Shlipak, M. G., Sarnak, M. J., Katz, R., Fried, L. F., Seliger, S. L., Newman, A. B., Siscovick, D. S., & Stehman-Breen, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043161 · Cited by 1,249
Self-citationWriting committee, Unwin, N., Shaw, J., Zimmet, P., & Alberti, K. G. M. M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00835.x · Cited by 1,108
Vasan, R. S., Larson, M. G., Leip, E. P., Kannel, W. B., & Levy, D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06710-1 · Cited by 1,072
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Stevens, L. A., Coresh, J., Schmid, C. H., Feldman, H. I., Froissart, M., Kusek, J., Rossert, J., Van Lente, F., Bruce, R. D., Zhang, Y. (., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.018 · Cited by 1,037
Metadata
- Authors
- Shlipak, M. G., Katz, R., Sarnak, M. J., Fried, L. F., Newman, A. B., Stehman-Breen, C., Seliger, S. L., Kestenbaum, B., Psaty, B., Tracy, R. P., & Siscovick, D. S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2006-08-15
- Volume
- 145
- Issue
- 4
- Pages
- 237-246
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2129213988
- Cited by
- 540
- References
- 39
- FWCI
- 24.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease. https://app.cochat.ai/papers/10.7326/0003-4819-145-4-200608150-00003
- The paper
- Shlipak, M. G., Katz, R., Sarnak, M. J., Fried, L. F., Newman, A. B., Stehman-Breen, C., Seliger, S. L., Kestenbaum, B., Psaty, B., Tracy, R. P., & Siscovick, D. S. (2006). Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-145-4-200608150-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.